BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC

Category	Detail
Condition	Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms	BAG3+ CAF-T Cell Neighborhood associated with treatment resistance
Target Population	Patients undergoing neoadjuvant chemoimmunotherapy (NCIT)
Care Setting	Oncology clinical practice

Over 40% of NSCLC patients fail to achieve major pathological response (MPR) after NCIT.
BAG3+ CAF-T Cell Neighborhood is significantly more abundant in non-responders (nMPR) compared to responders (MPR).
The predictive value of BAG3+ CAF-T Cell Neighborhood outperformed other indicators in identifying non-response to NCIT.
AUC values for BAG3+IFITM2+ CAFs and BAG3+CD8+ T cells indicate strong predictive potential.
OS and DFS are significantly decreased in patients with high BAG3+ CAF-T Cell Neighborhood.

Utilize single-cell RNA sequencing to identify biomarkers associated with treatment response.

Consider BAG3+ CAF-T Cell Neighborhood as a potential biomarker for predicting non-response to NCIT.

Assess the abundance of BAG3+ CAF-T Cell Neighborhood in pre-treatment tissue samples.

Patients with high levels of BAG3+ CAF-T Cell Neighborhood may have poorer survival outcomes.

Patients with resectable NSCLC undergoing NCIT.

Current biomarkers like PD-L1 and TMB have limited sensitivity and specificity in predicting NCIT response.

Integrate BAG3+ CAF-T Cell Neighborhood assessment in pre-treatment evaluations.
Utilize multiplex immunofluorescence for validation of predictive biomarkers.

Clinical Scorecard: BAG3+ CAF-T Cell Microenvironment as a Predictor of Neoadjuvant Chemoimmunotherapy Resistance in Non-Small Cell Lung Cancer